{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"AMGN","limit":50},"count":50,"signals":[{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":100,"match_count":13,"context":"iances. Whether we use our own sales and marketing forces or a third partys services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hos","filed_date":"2026-02-13","accession":"0000318154-26-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":165,"context":"other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, a number of legislative and regulatory proposals have been introduced and/or signed into law to lower drug prices. These include the IRA that enables the U.S. g","filed_date":"2026-02-13","accession":"0000318154-26-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and nine months ended September 30, 2025, the gross amounts of our UTBs increased by $45 million and $145million, respectively, as","filed_date":"2025-11-05","accession":"0000318154-25-000072","full_text":"https://origin.rootz.global/static/filing/0000318154-25-000072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":20,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and six months ended June 30, 2025, the gross amounts of our UTBs increased by $60 million and $100million, respectively, as a resu","filed_date":"2025-08-06","accession":"0000318154-25-000056","full_text":"https://origin.rootz.global/static/filing/0000318154-25-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":71,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.10During the three months ended March 31, 2025, the gross amounts of our UTBs increased by $40 million as a result of tax positions taken during the","filed_date":"2025-05-02","accession":"0000318154-25-000020","full_text":"https://origin.rootz.global/static/filing/0000318154-25-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Dr. Mary E. Klotman, Ms. Ellen J. Kullman, and Ms. Amy E. Miles; |  | |  |  |  |  | |  |  2. |  To hold an advisory vote to approve our executive compensation; |  | |  |  |  |  | |  |  3. |  To ratify the selection of Ernst & Young LLP as","filed_date":"2025-04-09","accession":"0000950170-25-052315","full_text":"https://origin.rootz.global/static/filing/0000950170-25-052315.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":37,"context":"nvestments for long-term growth. We also recognize that stockholders who support investment in developing innovative medicines require an appropriate return on the capital they commit to Amgen. |  |  Invested $7.1 billion in 2024 for long-term growth($6.0 billion inresearch and development; and $1.1 billion incapital expenditures, including investments in expansion of our manufacturing facilities). |  | |  |  Reduced","filed_date":"2025-04-09","accession":"0000950170-25-052315","full_text":"https://origin.rootz.global/static/filing/0000950170-25-052315.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":169,"context":"other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced and/or signed into law to lower drug prices. These i","filed_date":"2025-02-14","accession":"0000318154-25-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-25-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":63,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and nine months ended September 30, 2024, the gross amounts of our UTBs increased by $40 million and $120million, respectively, as","filed_date":"2024-10-31","accession":"0000318154-24-000044","full_text":"https://origin.rootz.global/static/filing/0000318154-24-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":66,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and six months ended June 30, 2024, the gross amounts of our UTBs increased by $40 million and $80million, respectively, as a resul","filed_date":"2024-08-07","accession":"0000318154-24-000035","full_text":"https://origin.rootz.global/static/filing/0000318154-24-000035.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":62,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three months ended March 31, 2024, the gross amounts of our UTBs increased by $40 million as a result of tax positions taken during the c","filed_date":"2024-05-03","accession":"0000318154-24-000020","full_text":"https://origin.rootz.global/static/filing/0000318154-24-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":48,"context":"A. Bradway, Dr. Michael V. Drake, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Dr. Mary E. Klotman, Ms. Ellen J. Kullman, and Ms. Amy E. Miles; | | |  | |  |  2. |  |  To hold an advisory vote to approve our executive compensation; | | |  | |  |  3. |  |  To approve our proposed Amgen Inc. Second Amended and Restated","filed_date":"2024-04-17","accession":"0001193125-24-099062","full_text":"https://origin.rootz.global/static/filing/0001193125-24-099062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":42,"context":"nize that stockholders who support investment in developing innovative medicines require an appropriate return on the capital they commit to Amgen. We returned excess capital through dividends. |  |  Invested $33.7 billion for long-term growth: $27.8 billion in acquisitions; $4.8 billion in research and development; and $1.1 billion in capital expenditures, including investments in manufacturing sites that support our","filed_date":"2024-04-17","accession":"0001193125-24-099062","full_text":"https://origin.rootz.global/static/filing/0001193125-24-099062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":100,"match_count":13,"context":"iances. Whether we use our own sales and marketing forces or a third partys services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hos","filed_date":"2024-02-14","accession":"0000318154-24-000011","full_text":"https://origin.rootz.global/static/filing/0000318154-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":156,"context":"other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced and/or signed into law that attempt to lower drug pr","filed_date":"2024-02-14","accession":"0000318154-24-000011","full_text":"https://origin.rootz.global/static/filing/0000318154-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. See our Annual Report on Form 10-K","filed_date":"2023-10-31","accession":"0000318154-23-000064","full_text":"https://origin.rootz.global/static/filing/0000318154-23-000064.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":11,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. 12 We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. See our Annual Report on Form 1","filed_date":"2023-08-04","accession":"0000318154-23-000053","full_text":"https://origin.rootz.global/static/filing/0000318154-23-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. See our Annual Report on Form 10-K","filed_date":"2023-04-28","accession":"0000318154-23-000029","full_text":"https://origin.rootz.global/static/filing/0000318154-23-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":43,"context":"ors are Dr.WandaM. Austin, Mr.RobertA. Bradway, Dr.MichaelV. Drake, Dr.BrianJ. Druker, Mr.RobertA. Eckert, Mr.GregC. Garland, Mr.CharlesM. Holley, Jr., Dr.S. Omar Ishrak, Dr.Tyler Jacks, Ms.EllenJ. Kullman, Ms.AmyE. Miles, Dr.RonaldD. Sugar, and Dr.R.Sanders Williams; | | |  |  |  | | |  |  |  2. |  |  To hold an advisory vote on the frequency of future stockholder advisory votes to approve executive","filed_date":"2023-04-06","accession":"0001193125-23-093947","full_text":"https://origin.rootz.global/static/filing/0001193125-23-093947.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":40,"context":"ensation |  |  |  40 |  | | |  |  | | |  Item3Advisory Vote to Approve Our Executive Compensation |  |  |  41 |  | | |  |  | | |  CompensationDiscussionandAnalysis |  |  |  42 |  | | |  |  | | |  Our Named Executive Officers |  |  |  42 |  | | |  |  |  |  |  | | |  |  | | |  Our Strategy |  |  |  42 |  | | |  |  | | |  Our Approach to Environmental Sustainability, Social Responsibility, and Corporate Governance |  |  |","filed_date":"2023-04-06","accession":"0001193125-23-093947","full_text":"https://origin.rootz.global/static/filing/0001193125-23-093947.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"4.3 |  |  No Governmental Approvals Required |  |  |  55 |  | | |  4.4 |  |  Subsidiaries |  |  |  55 |  | | |  4.5 |  |  Financial Statements |  |  |  55 |  | | |  4.6 |  |  No Other Liabilities; No Material Adverse Effect |  |  |  55 |  | | |  4.7 |  |  Governmental Regulation |  |  |  55 |  | | |  4.8 |  |  Litigation |  |  |  55 |  | | |  4.9 |  |  Binding Obligations |  |  |  56 |  | | |  4.10 |  |  No Default |  |","filed_date":"2023-03-09","accession":"0001193125-23-066144","full_text":"https://origin.rootz.global/static/filing/0001193125-23-066144.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":100,"match_count":16,"context":"iances. Whether we use our own sales and marketing forces or a third partys services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hos","filed_date":"2023-02-09","accession":"0000318154-23-000017","full_text":"https://origin.rootz.global/static/filing/0000318154-23-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":86,"context":"Pandemic The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations. A breakdown of our information technol","filed_date":"2023-02-09","accession":"0000318154-23-000017","full_text":"https://origin.rootz.global/static/filing/0000318154-23-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"4.3 |  |  No Governmental Approvals Required |  |  |  41 |  | | |  4.4 |  |  Subsidiaries |  |  |  41 |  | | |  4.5 |  |  Financial Statements |  |  |  41 |  | | |  4.6 |  |  No Other Liabilities; No Material Adverse Effect |  |  |  42 |  | | |  4.7 |  |  Governmental Regulation |  |  |  42 |  | | |  4.8 |  |  Litigation |  |  |  42 |  | | |  4.9 |  |  Binding Obligations |  |  |  42 |  | | |  4.10 |  |  No Default |  |","filed_date":"2022-12-22","accession":"0001193125-22-311112","full_text":"https://origin.rootz.global/static/filing/0001193125-22-311112.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":13,"context":"e Transaction Agreement not having been terminated in accordance with its terms; | | |  |  |  |  the accuracy of each of the Parties representations and warranties, subject to certain materiality and material adverse effect exceptions; | | |  |  |  |  the performance by each Party, in all material respects, with all of such Partys covenants and agreements under the Transaction Agreement; and | | |  |  |  |  the absence","filed_date":"2022-12-12","accession":"0001193125-22-302256","full_text":"https://origin.rootz.global/static/filing/0001193125-22-302256.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. 11 See Part II, Item 1A, Risk Fact","filed_date":"2022-11-04","accession":"0000318154-22-000055","full_text":"https://origin.rootz.global/static/filing/0000318154-22-000055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":14,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. 11 See Item 2. Managements Discuss","filed_date":"2022-08-05","accession":"0000318154-22-000041","full_text":"https://origin.rootz.global/static/filing/0000318154-22-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":9,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. See Item 2. Managements Discussion","filed_date":"2022-04-28","accession":"0000318154-22-000021","full_text":"https://origin.rootz.global/static/filing/0000318154-22-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":38,"context":"rectors are Dr. Wanda M. Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Charles M. Holley, Jr., Dr. S. Omar Ishrak, Dr. Tyler Jacks, Ms. Ellen J. Kullman, Ms. Amy E. Miles, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams; | | |  |  |  | | |  |  |  2. |  |  To hold an advisory vote to approve our executive compensation; | | |  |  |  | | |  |  |  3.","filed_date":"2022-04-05","accession":"0001193125-22-096161","full_text":"https://origin.rootz.global/static/filing/0001193125-22-096161.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":37,"context":"ecutive Compensation |  |  |  40 |  | | |  |  |  |  |  | | |  |  | | |  Executive Compensation |  |  |  41 |  | | |  |  | | |  Compensation Discussion and Analysis |  |  |  41 |  | | |  |  | | |  Our Named Executive Officers |  |  |  41 |  | | |  |  | | |  Our Strategy |  |  |  41 |  | | |  |  | | |  Our Approach to Environmental Sustainability, Social Responsibility, and Corporate Governance |  |  |  43 |  | | |  |  |","filed_date":"2022-04-05","accession":"0001193125-22-096161","full_text":"https://origin.rootz.global/static/filing/0001193125-22-096161.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":100,"match_count":16,"context":"iances. Whether we use our own sales and marketing forces or a third partys services varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hos","filed_date":"2022-02-16","accession":"0000318154-22-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-22-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":78,"context":"Pandemic The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, manufacturing, supply chains, distribution systems, product development, product sales, business and results of operations. A breakdown, cyberattack or informatio","filed_date":"2022-02-16","accession":"0000318154-22-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-22-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":39,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for the years ended on or before December 31, 2009. During the three and nine mont","filed_date":"2021-11-03","accession":"0000318154-21-000045","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":37,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for the years ended on or before December 31, 2009. During the three and six month","filed_date":"2021-08-04","accession":"0000318154-21-000034","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":12,"context":"of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our consolidated financial statements. We are no longer subject to U.S. federal income tax examinations for the years ended on or before December 31, 2009. During the three months ended March 31,","filed_date":"2021-04-28","accession":"0000318154-21-000019","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":44,"context":"-sustaining jobs over the next ten years, and as a founding sponsor of Lazarex Cancer Foundations IMPACT (Improving Patient Access to Cancer Clinical Trials) program, focused on improving patient enrollment, minority participation, and equitable access in cancer clinical trials.  **Stockholder Engagement:**We are also guided by, and appreciative of, the perspectives of our stockholders as expressed t","filed_date":"2021-04-06","accession":"0001193125-21-107038","full_text":"https://origin.rootz.global/static/filing/0001193125-21-107038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":37,"context":"y Vote to Approve Our Executive Compensation |  |  36 | | |  |  |  | | |  |  | | |  Executive Compensation |  |  41 | | |  |  | | |  Compensation Discussion and Analysis |  |  41 | | |  |  | | |  Our Named Executive Officers |  |  41 | | |  |  | | |  Our Strategy |  |  42 | | |  |  | | |  Our Compensation Best Practices |  |  43 | | |  |  | | |  Aligning Pay With Performance, Executing on Our Strategic Priorities, and D","filed_date":"2021-04-06","accession":"0001193125-21-107038","full_text":"https://origin.rootz.global/static/filing/0001193125-21-107038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"es that had the potential for significant benefit in a serious or life-threatening condition and when site resources enabled new patients to be enrolled safely and monitored closely, we continued enrollment. For clinical trials experiencing uncertainty with regard to the trial sites ability to ensure subject safety or data integrity at that time, we temporarily paused enrollment. We remain focused on","filed_date":"2021-02-09","accession":"0000318154-21-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"platform_shift","strength":100,"match_count":16,"context":"icant alliances. Whether we use our own sales and marketing forces or a third partys varies across these markets. Such use typically depends on several factors, including the nature of entry into the new market, the size of an opportunity and operational capabilities. Together with our collaborators, we market our products to healthcare providers, including physicians or their clinics, dialysis centers, hos","filed_date":"2021-02-09","accession":"0000318154-21-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":74,"context":"Pandemic The COVID-19 pandemic, and the public and governmental effort to mitigate against the spread of the disease, have had, and are expected to continue to have, an adverse effect, and may have a material adverse effect, on our clinical trials, operations, supply chains, distribution systems, product development, product sales, business and results of operations. A breakdown, cyberattack or information security brea","filed_date":"2021-02-09","accession":"0000318154-21-000010","full_text":"https://origin.rootz.global/static/filing/0000318154-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":21,"context":"t material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: 28 Abbreviated New Dru","filed_date":"2020-10-29","accession":"0000318154-20-000060","full_text":"https://origin.rootz.global/static/filing/0000318154-20-000060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":17,"context":"t material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Abbreviated New Drug A","filed_date":"2020-07-29","accession":"0000318154-20-000048","full_text":"https://origin.rootz.global/static/filing/0000318154-20-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":17,"context":"t material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Abbreviated New Drug A","filed_date":"2020-05-01","accession":"0000318154-20-000031","full_text":"https://origin.rootz.global/static/filing/0000318154-20-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":40,"context":"ly oncology programs, including **AMG 510**, our KRASG12C small molecule inhibitor, that has enrolled a potentially pivotal Phase 2 monotherapy study in advanced non-small cell lung cancer, began enrollment of colorectal cancer patients in a Phase 2 monotherapy study, and is also being investigated as a treatment for a variety of other solid tumors. Outside of oncology, we have also advanced our pipe","filed_date":"2020-04-07","accession":"0001193125-20-100447","full_text":"https://origin.rootz.global/static/filing/0001193125-20-100447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":44,"context":"Item 2Advisory Vote to Approve Our Executive Compensation |  |  34 | | |  |  | | |  Executive Compensation |  |  38 | | |  |  | | |  Compensation Discussion and Analysis |  |  38 | | |  |  | | |  Our Named Executive Officers |  |  38 | | |  |  |  | | |  |  | | |  Our Strategy |  |  39 | | |  |  | | |  Our Compensation and Governance Best Practices |  |  40 | | |  |  | | |  Aligning Pay With Performance and Execution of","filed_date":"2020-04-07","accession":"0001193125-20-100447","full_text":"https://origin.rootz.global/static/filing/0001193125-20-100447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":48,"context":"blic scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, may limit our ability to set or adjust the price of our products based on their value, which could have a material adverse effect on our business. In the United States, a number of legislative and regulatory proposals have been introduced in an attempt to lower drug prices. These include proposals that would, for example, allow","filed_date":"2020-02-12","accession":"0000318154-20-000017","full_text":"https://origin.rootz.global/static/filing/0000318154-20-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":22,"context":"|  |  |  | | |  |  |  4.4 |  |  Subsidiaries |  |  |  49 |  | | |  |  |  |  | | |  |  |  4.5 |  |  Financial Statements |  |  |  50 |  | | |  |  |  |  | | |  |  |  4.6 |  |  No Other Liabilities; No Material Adverse Effect |  |  |  50 |  | | |  |  |  |  | | |  |  |  4.7 |  |  Governmental Regulation |  |  |  50 |  | | |  |  |  |  | | |  |  |  4.8 |  |  Litigation |  |  |  50 |  | | |  |  |  |  | | |  |  |  4.9 |  |  Bi","filed_date":"2019-12-12","accession":"0001193125-19-312129","full_text":"https://origin.rootz.global/static/filing/0001193125-19-312129.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":10,"context":"t material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Novartis Breach of Con","filed_date":"2019-10-30","accession":"0000318154-19-000046","full_text":"https://origin.rootz.global/static/filing/0000318154-19-000046.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":21,"context":"t material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Novartis Breach of Con","filed_date":"2019-07-31","accession":"0000318154-19-000037","full_text":"https://origin.rootz.global/static/filing/0000318154-19-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AMGN","company":"AMGEN INC","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":42,"context":". Austin, Mr. Robert A. Bradway, Dr. Brian J. Druker, Mr. Robert A. Eckert, Mr. Greg C. Garland, Mr. Fred Hassan, Dr. Rebecca M. Henderson, Mr. Charles M. Holley, Jr., Dr. Tyler Jacks, Ms. Ellen J. Kullman, Dr. Ronald D. Sugar, and Dr. R. Sanders Williams; | | |  |  |  | | |  |  |  2. |  |  To hold an advisory vote to approve our executive compensation; | | |  |  |  | | |  |  |  3. |  |  To ratify th","filed_date":"2019-04-08","accession":"0001193125-19-100704","full_text":"https://origin.rootz.global/static/filing/0001193125-19-100704.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"9ce62f92ab6c2684aeb5780de8cb6e69fc632fbaa8c5d41eac4fb4314642b906","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"43a496163be640a0f4da236cb5747f19d275c22932493cbd4b92f55165b40059","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":430,"hourly_limit":500,"remaining":70,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}